Atlas Trials

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Clinical trial NCT05015621 · UNKNOWN

Trial details

NCT number
NCT05015621
Sponsor
Hutchison Medipharma Limited
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Neuroendocrine Carcinoma
Start date
2021-09-18
Primary completion
2025-05-31
Enrollment
194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.